Bratislava Medical Journal Vol.123, No.2, p.120

Bratislava Medical Journal Vol.123, No.2, p.120–124, 2022

Published Monthly, in English
Founded: 1919
ISSN 0006-9248
(E)ISSN 1336-0345

Impact factor 1.564

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Bratislava Medical Journal Vol.123, No.2, p.120–124, 2022
Title: COVID-19 outcomes in patients with antiphospholipid syndrome: a retrospective cohort study
Author: A. Erden, O. Karakas, B. Armagan, S. C. Guven, B. Ozdemir, E. Atalar, H. Apaydin, E. Usul, I. Ates , A. Omma, O. Kucuksahin

Abstract: BACKGROUND: Aim of this study is to investigate COVID-19 outcomes in patients with antiphospholipid syndrome (APS). METHODS: A retrospective cohort was formed from APS patients. Patients were screened for a record of positive SARS-CoV 2 PCR. In PCR‑positive patients, clinical data and information regarding COVID-19 outcomes were collected from medical records. RESULTS: A positive PCR test was detected in 9/53 APS patients, while 66.7 %, 33.3 % and 11.1 % of APS patients with COVID-19 were under hydroxychloroquine, LMWH or warfarin, and acetylsalicylic acid, respectively. There were 3/9 patients found to be hospitalized and one died. No new thrombotic event was reported in any of the patients during COVID-19 infection. CONCLUSION: Baseline use of hydroxychloroquine, antiaggregants and anticoagulants may be associated with an absence of new thrombotic event (Tab. 2, Ref. 33).

Keywords: antiphospholipid syndrome, COVID-19, outcome, thrombosis, mortality
	Published online: 23-Jan-2022
Year: 2022, Volume: 123, Issue: 2	Page From: 120, Page To: 124
doi:10.4149/BLL_2022_018
	download file

Aepress.sk